Bio-analytical Approach for Stability Studies of Bendroflumethiazide Materials

B. Veeraswami a* and V. M. K. Naveen a

a Department of chemistry, GITAM Institute of Science, GITAM Deemed to be University, Visakhapatnam, PIN-530045, India.

Authors’ contributions

This work was carried out in collaboration between both authors. Both authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i54B33780

(1) Dr. Giuseppe Murdaca, University of Genoa, Italy.
(1) N’ghaya Toulbe, National Institute of Materials Physics, Romania.
(2) Alaa Adnan Rashad, Al-Nahrain University, Iraq.
(3) Amani A. Husain, Al-Mustansiriyyah University, Iraq.

Received 01 October 2021
Accepted 06 December 2021
Published 11 December 2021

Original Research Article

ABSTRACT

In this paper a comprehensive study of stability related, and evidence based best practices of Bio-analytical stability on Bendroflumethiazide drug samples are studied. The proposed approach is very significant and essential for the drugs development process address the specify the acceptancy, purity, efficacy, prediction of strength and quality of the drugs. The stability study constituents several methods like Bench-Top, Auto-sampler, Freeze-Thaw, Dry-extract, Wet-extract, Short-term, long-Term stability studies at relative intervals results the complete stability information about the drug under the proposed and validated method. There ported out comes of this methos shows this drug have good stability according to ICH guidelines.

Keywords: Bio-analytical; bendroflumethiazide; auto-sampler; short term; wet-extract; ICH guidelines.

1. INTRODUCTION

Bendroflumethiazide formal brand name Aprinox is a thiamine diuretic used for the treat of hypertension. Bendroflumethiazide may be a thiamine diuretic [1-2] that acts at the start of the distal convoluted tubule (DCT) by inhibiting sodium reabsorption. As a consequence of more sodium hitting the supply ducts, water is lost. Bendroflumethiazide mark has a role to play in
the treatment of minor coronary wreck, but the diuretic loop could be safer for overload reduction. The Best use of bendroflumethiazide in hypertension [3] at present. Its structure shown in Fig. 1 and it was patented in 1958 & it was used for medical usage [4-7] in 1960. The mechanism of action of this drug as diuretic [8] nature it inhibit reabsorption of active chlorine increases the excretion of NaCl and H₂O. Which results exchange mechanism of Sodium-Potassium. In the hypertensive mechanism with carbonic anhydrase leads to forms very smooth muscles due to conductance between activated calcium-potassium. In the present study the stability study of the proposed validated method for quantification and validation of Bendroflumethiazide to assess the stability of the drug.

Bendroflumethiazide in concentration 100 µg/ml by weight 10 mg of Bendroflumethiazide standard and dissolved it in 100 ml of diluent. Second step take 1 ml of first solution prepared (100 µg/ml) and dissolved it with 10 ml of solvent to finally prepare the parent stock solution in concentration is 0.1 µg/ml.

2.3.2 Preparation standard of Bendroflumethiazide solutions

The parent stock solutions of Bendroflumethiazide parent stock liquid of 0.4 ml saturated into 10 ml vacuum bottles up to the mark with solvents have concentrations 320 ng/ml&40 ng/ml respectively. In the same way internal standard stock solution was prepared.

2.3.3 Preparation of standard solution

Typical solution was prepared by taking 0.5 ml, 0.2 ml, 0.3 ml and 0.5 ml of parent liquid, internal standard stock solution, plasma, acetonitrile and diluent in a centrifuged tube and centrifuged for about 15 min to mixing the contents at 5000 rpm excessive managed solution was isolated and filtered by micro filter with pore size 0.45 µ then inoculated to HPLC system.

2.3.4 Sample stock preparation

One pill (5 mg of Bendroflumethiazide) was weighed, note the average weight of the tablet. The pill was taken into a mortar and crushed into fine powder. 13.4 mg of tablet powder was weighed accurately and dissolved in 100 ml of diluent. From this take 0.8 ml and diluted to 100 ml with diluents. This is the sample stock with Bendroflumethiazide concentration 40 µg/ml.

2.3.5 Sample solution preparation

For sample preparation take 0.2 ml of plasma, 0.5 ml of sample stock, 0.3 ml of acetonitrile and 0.5 ml of IS, 0.5 ml of diluent were taken into a centrifuge tube and centrifuged about 15 min to precipitate all the proteins with 5000 rpm and collect the excessive solution into a vial and inject it into HPLC system.

2.4 Method Developed and Validation

A method was developed and validated [9] by LC-MS with isocratic approach have waters symmetry C₁₈ column with dimensions 150x4.6 mm with pore size 3.5 microns for chromatographic analysis. The author also
studied few drugs, and their bioanalytical quantification and validation studies gave good results [10-12]. The solvent Orthophosphoric acid with 0.1% strength and acetonitrile are taken in 60:40 proportions are administered into chromatogram for positive electron spry ionization method.

2.5 Stability Studies of the Proposed Method

In order to check the feasibility and stability of the proposed validated method by studying various Bio-analytical stability related studies like Bench-Top, Auto-sampler, Freeze-Thaw, Dry-extract, Wet-extract, Short-term, long-Term stability studies at various intervals gave the complete stability information about these drugs. As per the US FDA guidelines the LQC and HQC strengths & their plasma stability studies on six different copies are injected for each dose. In auto sampler stability the spiked rat plasma was placed at temperature 2-8°C for about twenty-four hours.

3. RESULTS AND DISCUSSIONS

3.1 Bench Top Stability

In Bench-Top method the sample solutions are placed on bench-top during the experiment for about six to twenty-four hours of the procedure of extraction after remove from the fridge took six replications have low and high strengths then inoculate to chromatogram the results are shown in Table 1 and it allows the Bench top stability.

**Acceptance criteria:** The Percent average exactness is in between 85-115 for eight specimens out of twelve samples. The minimum requirement of 80% of the matrix lot should meet the acceptance criteria. The reverse calculated strengths of LQC and HQC is less than or equal to 15%.

**Auto Sampler Stability:** In Auto-sampler stability method the pooled solutions are placed in to auto-sampler inoculated to injector. The reports are placed in Table 2 and it acceptancy was passed the Auto Sampler Stability.

**Acceptance criteria:** The reports of LQC, MQC and HQC samples shows less than or equal to 15% and LL QC reports less than or equal to 20%. The Percent average exactness is in between 80-115 for sixteen specimens out of twenty-four samples. At least 80% of the matrix lot should meet the acceptance requirements. The back measured concentration accuracy percent LQC, MQC & HQC is in the above boundaries and LL QC is in between 80-120 percent.

**Freeze-Thaw stability:** For six different concentrations of this drug samples the Freeze-Thaw stability study was carried and the results are placed in Table 3 for Bendroflumethiazide. It passed the freeze thaw stability.

Table 1. Bendroflumethiazide stability results of Bench-Top method

| Replicate No. | HQC          | LQC          | MQC          |
|---------------|--------------|--------------|--------------|
|               | Ostensible strength in ng/ml | Ostensible strength range in ng/ml |                     |
| 15.755        | 5.257        | 10.125       |              |
| (15.751-15.759) | (5.252-5.259) | (10.017-10.232) |                     |
| Area of analyte-peak |                     |                     |                     |
| 1             | 1.041x10⁵    | 0.361x10⁵    | 0.788x10⁵    |
| 2             | 1.022x10⁵    | 0.378x10⁵    | 0.775x10⁵    |
| 3             | 1.036x10⁵    | 0.385x10⁵    | 0.779x10⁵    |
| 4             | 1.018x10⁵    | 0.381x10⁵    | 0.785x10⁵    |
| 5             | 1.027x10⁵    | 0.393x10⁵    | 0.782x10⁵    |
| 6             | 1.034x10⁵    | 0.367x10⁵    | 0.794x10⁵    |
| Mean          | 1.030x10⁵    | 0.378x10⁵    | 0.784x10⁵    |
| SD            | 0.00882      | 0.01176      | 0.00674      |
| %CV           | 0.86         | 3.12         | 0.86         |
| % Mean Accuracy | 98.8%        | 98.5%        | 99.7%        |
Table 2. Auto sampler stability of Bendroflumethiazide

| Replicate No. | HQC  | MQC  | LQC  |
|---------------|------|------|------|
|               | Ostensible strength in ng/ml |      |      |
|               | 15.756 | 10.526 | 5.257 |
|               | Ostensible strength range in ng/ml |      |      |
|               | (15.751-15.759) | (10.522-10.528) | (5.253-5.259) |
| Analyte peak region |      |      |      |
| 1             | 1.061x10^5 | 0.748x10^5 | 0.342x10^5 |
| 2             | 1.066x10^5 | 0.756x10^5 | 0.333x10^5 |
| 3             | 1.064x10^5 | 0.749x10^5 | 0.330x10^5 |
| 4             | 1.069x10^5 | 0.732x10^5 | 0.364x10^5 |
| 5             | 1.073x10^5 | 0.726x10^5 | 0.351x10^5 |
| 6             | 1.075x10^5 | 0.738x10^5 | 0.335x10^5 |
| 7             | 1.061x10^5 | 0.349x10^5 | 0.349x10^5 |
| 8             | 1.074x10^5 | 0.755x10^5 | 0.351x10^5 |
| 9             | 1.082x10^5 | 0.764x10^5 | 0.355x10^5 |
| 10            | 1.056x10^5 | 0.761x10^5 | 0.342x10^5 |
| 11            | 1.047x10^5 | 0.774x10^5 | 0.363x10^5 |
| 12            | 1.055x10^5 | 0.753x10^5 | 0.347x10^5 |
| 13            | 1.061x10^5 | 0.742x10^5 | 0.338x10^5 |
| 14            | 1.062x10^5 | 0.749x10^5 | 0.326x10^5 |
| 15            | 1.078x10^5 | 0.736x10^5 | 0.339x10^5 |
| 16            | 1.069x10^5 | 0.738x10^5 | 0.341x10^5 |
| 17            | 1.057x10^5 | 0.769x10^5 | 0.374x10^5 |
| 18            | 1.042x10^5 | 0.772x10^5 | 0.371x10^5 |
| 19            | 1.066x10^5 | 0.774x10^5 | 0.369x10^5 |
| 20            | 1.053x10^5 | 0.758x10^5 | 0.364x10^5 |
| 21            | 1.072x10^5 | 0.743x10^5 | 0.350x10^5 |
| 22            | 1.081x10^5 | 0.750x10^5 | 0.355x10^5 |
| 23            | 1.049x10^5 | 0.749x10^5 | 0.362x10^5 |
| 24            | 1.063x10^5 | 0.764x10^5 | 0.361x10^5 |
| n             | 24    | 24    | 24    |
| Average       | 1.064x10^5 | 0.757x10^5 | 0.351x10^5 |
| SD            | 0.01059 | 0.01277 | 0.01355 |
| %CV           | 0.99  | 1.69  | 3.87  |
| % Average Accuracy | 98.8% | 98.6% | 98.4% |

Table 3. Bendroflumethiazide freeze thaw stability

| Trial No. | HQC  | LQC  | MQC  |
|-----------|------|------|------|
|           | Ostensible strength in ng/ml |      |      |
|           | 15.755 | 5.257 | 10.425 |
|           | Ostensible strength range in ng/ml |      |      |
|           | (15.751-15.759) | (5.252-5.259) | (10.321-10.581) |
| Area of analyte signal |      |      |      |
| 1          | 1.026x10^5 | 0.314x10^5 | 0.727x10^5 |
| 2          | 1.021x10^5 | 0.308x10^5 | 0.741x10^5 |
| 3          | 1.032x10^5 | 0.314x10^5 | 0.732x10^5 |
| 4          | 1.037x10^5 | 0.301x10^5 | 0.749x10^5 |
| 5          | 1.041x10^5 | 0.322x10^5 | 0.725x10^5 |
| 6          | 1.045x10^5 | 0.335x10^5 | 0.718x10^5 |
| n          | 6     | 6     | 6     |
| Average    | 1.034x10^5 | 0.316x10^5 | 0.732x10^5 |
| SD         | 0.00911 | 0.01178 | 0.01131 |
| %CV        | 0.88  | 3.73  | 1.55  |
| Average percent of accuracy | 98.8% | 98.5% | 99.5% |
Acceptance criteria: The criteria to accept this method have strength in between 85-115 % of LQC, HQC and the % CV is less than or equal to 15 %.

Wet method of Extract: At different time intervals of 12 hours, 18 hours Wet-Extract stability was studied on these drugs reported the results are shown in Table 4 & Table 5. It was passed.

Acceptance criteria: The criteria to accept this method have strength in between 85-115 % of LQC, HQC and the % CV is less than or equal to 15 %.

Dry Extract: Dry Extract stability was performed at two different time intervals of 12 hours and 18 hours for this drug shows the reported results are accepted. The results are shown in Table 6 & Table 7.

Acceptance criteria: The criteria to accept this method have strength in between 85-115 % of LQC, HQC and the % CV is less than or equal to 15 %.

Short-Term Stability: The Short-Term study on these drugs for different strengths were studied and it was allowed. The results are shown in Table 8.

Acceptance criteria: The criteria to accept this method have strength in between 85-115 % of LQC, HQC and the % CV is less than or equal to 15 %.

Table 4. Bendroflumethiazide stability in Wet extract at 12 Hr

| Trial No. | HQC | LQC | MQC |
|----------|-----|-----|-----|
|           | Ostensible strength in ng/ml |        |     |
|           | 15.755 | 5.257 | 10.111 |
|           | Ostensible strength range in ng/ml |        |     |
|           | (15.751-15.759) | (5.252-5.259) | (10.079-10.222) |
| Area of analyte signal |  |  |  |
| 1 | 1.074x10^5 | 0.332x10^5 | 0.779x10^5 |
| 2 | 1.073x10^5 | 0.338x10^5 | 0.785x10^5 |
| 3 | 1.068x10^5 | 0.342x10^5 | 0.782x10^5 |
| 4 | 1.085x10^5 | 0.347x10^5 | 0.774x10^5 |
| 5 | 1.079x10^5 | 0.355x10^5 | 0.762x10^5 |
| 6 | 1.081x10^5 | 0.363x10^5 | 0.775x10^5 |
| n | 6 | 6 | 6 |
| Mean | 1.077x10^5 | 0.346x10^5 | 0.776x10^5 |
| SD | 0.00615 | 0.01137 | 0.00808 |
| %CV | 0.57 | 3.29 | 1.04 |
| % Mean Accuracy | 99.8% | 98.5% | 98.1% |

Table 5. Bendroflumethiazide stability in Wet extract at 18 Hr

| Trial No. | HQC | LQC | MQC |
|----------|-----|-----|-----|
|           | Ostensible strength in ng/ml |        |     |
|           | 15.623 | 5.236 | 10.235 |
|           | Ostensible strength range in ng/ml |        |     |
|           | (15.521-15.759) | (5.212-5.259) | (10.104-10.368) |
| Area of analyte signal |  |  |  |
| 1 | 1.041x10^5 | 0.387x10^5 | 0.789x10^5 |
| 2 | 1.045x10^5 | 0.376x10^5 | 0.781x10^5 |
| 3 | 1.052x10^5 | 0.383x10^5 | 0.774x10^5 |
| 4 | 1.038x10^5 | 0.377x10^5 | 0.777x10^5 |
| 5 | 1.044x10^5 | 0.359x10^5 | 0.750x10^5 |
| 6 | 1.059x10^5 | 0.368x10^5 | 0.763x10^5 |
| n | 6 | 6 | 6 |
| Average | 1.047x10^5 | 0.375x10^5 | 0.772x10^5 |
| SD | 0.00771 | 0.01018 | 0.01388 |
| %CV | 0.74 | 2.71 | 1.80 |
| %Average Accuracy | 99.1% | 98.2% | 98.8% |
### Table 6. Bendroflumethiazide stability in Dry extract at 12 Hr

| Trial no. | HQC  | LQC  | MQC  |
|-----------|------|------|------|
|           | (15.328-15.629) | (5.310-5.759) | (10.215-10.426) |
| Ostensible strength in ng/ml | 15.418 | 5.528 | 10.329 |
| Ostensible strength range in ng/ml | 15.328-15.629 | 5.310-5.759 | 10.215-10.426 |
| Area of analyte signal | | | |
| n | 6 | 6 | 6 |
| Average | 1.032x10^5 | 0.365x10^5 | 0.737x10^5 |
| SD | 0.00768 | 0.00692 | 0.01026 |
| %CV | 0.74 | 1.89 | 1.39 |
| %Average Accuracy | 99.5% | 98.3% | 98.7% |

### Table 7. Bendroflumethiazide stability in dry extract at 18 Hr

| Replicate No. | HQC  | LQC  | MQC  |
|---------------|------|------|------|
|               | (15.478-15.759) | (5.242-5.413) | (10.174-10.316) |
| Ostensible strength in ng/ml | 15.629 | 5.314 | 10.255 |
| Ostensible strength range in ng/ml | 15.478-15.751 | 5.242-5.413 | 10.174-10.316 |
| Area of analyte signal | | | |
| n | 6 | 6 | 6 |
| Average | 1.031x10^6 | 0.356x10^5 | 0.736x10^5 |
| SD | 0.00656 | 0.01094 | 0.01626 |
| %CV | 0.64 | 3.07 | 2.21 |
| Mean-accuracy | 99.2% | 98.4% | 98.5% |

### Table 8. Bendroflumethiazide short-term stability

| Trial no. | HQC  | LQC  | MQC  |
|-----------|------|------|------|
|           | (15.428-15.751) | (5.689-5.896) | (10.524-10.783) |
| Ostensible strength in ng/ml | 15.315 | 5.758 | 10.621 |
| Ostensible strength range in ng/ml | 15.428-15.751 | 5.689-5.896 | 10.524-10.783 |
| Area of analyte signal | | | |
| n | 6 | 6 | 6 |
| Mean | 1.045x10^6 | 0.358x10^5 | 0.789x10^5 |
| SD | 0.01276 | 0.01160 | 0.00480 |
| %CV | 1.22 | 3.24 | 0.61 |
| % Mean Accuracy | 99.8% | 98.7% | 98.4% |
### Table 9. Bendroflumethiazide long-term stability at day-1

| Trial no. | HQC   | LQC   | MQC   |
|-----------|-------|-------|-------|
|           | Ostensible strength in ng/ml |       |       |
|           | 15.358 | 5.758 | 10.621|
|           | Ostensible strength range in ng/ml |       |       |
|           | (15.2758-15.512) | (5.258-5.896) | (10.524-10.778) |
|           | Area of analyte signal |       |       |
| 1         | 1.042x10^5 | 0.347x10^5 | 0.734x10^5 |
| 2         | 1.057x10^5 | 0.326x10^5 | 0.725x10^5 |
| 3         | 1.063x10^5 | 0.378x10^5 | 0.701x10^5 |
| 4         | 1.041x10^5 | 0.374x10^5 | 0.726x10^5 |
| 5         | 1.032x10^5 | 0.381x10^5 | 0.718x10^5 |
| 6         | 1.058x10^5 | 0.386x10^5 | 0.722x10^5 |
| n         | 6      | 6      | 6     |
| Mean      | 1.049x10^5 | 0.365x10^5 | 0.721x10^5 |
| SD        | 0.01219 | 0.02363 | 0.01114 |
| %CV       | 1.16   | 6.47   | 1.54  |
| Mean-Accuracy | 98.8%  | 98.5%  | 98.2% |

### Table 10. Bendroflumethiazide long-term stability at day-7

| Trial no. | HQC   | LQC   | MQC   |
|-----------|-------|-------|-------|
|           | Ostensible strength in ng/ml |       |       |
|           | 15.125 | 5.268 | 10.241|
|           | Ostensible strength range in ng/ml |       |       |
|           | (15.104-15.187) | (5.122-5.342) | (10.127-10.263) |
|           | Area of analyte signal |       |       |
| 1         | 0.942x10^5 | 0.325x10^5 | 0.704x10^5 |
| 2         | 0.957x10^5 | 0.326x10^5 | 0.705x10^5 |
| 3         | 0.963x10^5 | 0.324x10^5 | 0.701x10^5 |
| 4         | 0.941x10^5 | 0.325x10^5 | 0.706x10^5 |
| 5         | 0.932x10^5 | 0.328x10^5 | 0.708x10^5 |
| 6         | 0.958x10^5 | 0.327x10^5 | 0.702x10^5 |
| n         | 6      | 6      | 6     |
| Mean      | 0.948x10^5 | 0.325x10^5 | 0.704x10^5 |
| SD        | 0.01219 | 0.00147 | 0.00258 |
| %CV       | 1.28   | 0.45   | 0.37  |
| % Mean-Accuracy | 90.71%  | 89.77%  | 98.59% |

### Table 11. Bendroflumethiazide long-term stability at day-14

| Trial no. | HQC   | LQC   | MQC   |
|-----------|-------|-------|-------|
|           | Ostensible strength in ng/ml |       |       |
|           | 15.321 | 5.711 | 10.521|
|           | Ostensible strength range in ng/ml |       |       |
|           | (15.212-15.341) | (5.676-5.831) | (10.502-10.683) |
|           | Area of analyte signal |       |       |
| 1         | 0.912x10^5 | 0.275x10^5 | 0.634x10^5 |
| 2         | 0.913x10^5 | 0.276x10^5 | 0.635x10^5 |
| 3         | 0.903x10^5 | 0.274x10^5 | 0.631x10^5 |
| 4         | 0.901x10^5 | 0.275x10^5 | 0.636x10^5 |
| 5         | 0.912x10^5 | 0.278x10^5 | 0.638x10^5 |
| 6         | 0.914x10^5 | 0.277x10^5 | 0.632x10^5 |
| n         | 6      | 6      | 6     |
| Mean      | 0.9092x10^5 | 0.275x10^5 | 0.634x10^5 |
| SD        | 0.00564 | 0.00147 | 0.00258 |
| %CV       | 0.62   | 0.53   | 0.41  |
| % Mean Accuracy | 100.05%  | 75.96%  | 88.79% |
Table 12. Bendroflumethiazide long-term stability at day-21

| Trial no. | HQC | LQC | MQC |
|-----------|-----|-----|-----|
|           | Ostensible strength in ng/ml |     |     |
| 15.324    | 15.324 | 15.324 | 15.324 |
| 15.227-15.451 | (5.089-5.196) | (10.074-10.153) |     |
|           | Ostensible strength range in ng/ml |     |     |
|           | (15.227-15.451) | (5.089-5.196) | (10.074-10.153) |
|           | Area of analyte signal |     |     |
| 1         | 0.852x10^5 | 0.255x10^5 | 0.594x10^5 |
| 2         | 0.853x10^5 | 0.256x10^5 | 0.595x10^5 |
| 3         | 0.853x10^5 | 0.254x10^5 | 0.591x10^5 |
| 4         | 0.851x10^5 | 0.255x10^5 | 0.596x10^5 |
| 5         | 0.852x10^5 | 0.258x10^5 | 0.598x10^5 |
| 6         | 0.854x10^5 | 0.257x10^5 | 0.592x10^5 |
| n         | 6   | 6   | 6   |
| Average   | 0.852x10^5 | 0.255x10^5 | 0.594x10^5 |
| SD        | 0.12 | 0.58 | 0.43 |
| %CV       | 81.53% | 70.44% | 83.19% |
| %Average Accuracy | 81.53% | 70.44% | 83.19% |

Table 13. Bendroflumethiazide long-term stability at day-28

| Trial no. | HQC | LQC | MQC |
|-----------|-----|-----|-----|
|           | Ostensible strength in ng/ml |     |     |
| 15.315    | 15.315 | 15.315 | 15.315 |
| 15.428-15.751 | (5.689-5.896) | (10.524-10.783) |     |
|           | Ostensible strength range in ng/ml |     |     |
|           | (15.428-15.751) | (5.689-5.896) | (10.524-10.783) |
|           | Area of analyte signal |     |     |
| 1         | 0.802x10^5 | 0.241x10^5 | 0.562x10^5 |
| 2         | 0.803x10^5 | 0.241x10^5 | 0.565x10^5 |
| 3         | 0.803x10^5 | 0.242x10^5 | 0.561x10^5 |
| 4         | 0.801x10^5 | 0.243x10^5 | 0.596x10^5 |
| 5         | 0.802x10^5 | 0.242x10^5 | 0.568x10^5 |
| 6         | 0.804x10^5 | 0.241x10^5 | 0.562x10^5 |
| n         | 6   | 6   | 6   |
| Mean      | 0.8025x10^5 | 0.2417x10^5 | 0.569x10^5 |
| SD        | 0.00105 | 0.00082 | 0.01348 |
| %CV       | 0.13 | 0.34 | 2.37 |
| % Mean Accuracy | 76.79% | 66.76% | 79.69% |

Long-Term Stability: In long term stability study, reveals how these drugs are stable can be studied for about 1, 7, 14, 21 and 28 days shows the %CV and average accuracy for Bendroflumethiazide is found to be within the acceptable limit and it passed the Long-Term stability. The results are shown in Table 9 – Table 13.

4. CONCLUSIONS

The proposed bio-analytical stability studies on Bendroflumethiazide constitutes several studies like Bench-Top stability, Auto sampler stability, Freeze Thaw stability, Wet Extraction stability, Dry Extract stability, Short term stability and Long term stability results supports the method is validated and the drug Bendroflumethiazide shows good stability under the various experimental conditions repots their percentages of exactness is in between 85-115 %. The LQC, MQC and HQC samples shows less than or equal to 15 % and LL QC reports less than or equal to 20 %. The proposed methods meets the minimum criteria of 80% of the matrix lot. The reverse calculated and measured strengths of accuracy percent LQC, MQC & HQC is in the above boundaries and LL QC is in between 80-120 %.

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the
authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Dvorak MM, Joussineau CD, Carter DH, Pisitkun T, Knepper MA, Gamba G, Kemp PJ, Riccardi D. Thiazide Diuretics Directly Induce Osteoblast Differentiation and Mineralized Nodule Formation by Interacting with a Sodium Chloride Co-Transporter in Bone. Journal of the American Society of Nephrology. 2007; 18(9):2509–2516.

2. Moser M. Fifty Years of Thiazide Diuretic Therapy for Hypertension. Archives of Internal Medicine. 2009;169(20):1851–1851.

3. Sato A, Terata K, Miura H, Toyama K, Lober4iza FR, Hatoum OA, Saito T, Sakuma I, Guterman DD. Mechanism of vasodilatation to adenosine in coronary arterioles from patients with heart disease. American Journal of Physiology-Heart and Circulatory Physiology. 2005;288(4):H1633-H1640.

4. Monroy A, Plata C, Hebert SC, Gamba G. Characterization of the thiazide-sensitive Na(+)-Cl(-) cotransporter: a new model for ions and diuretics interaction. Am J Physiol Renal Physiol. 2000;279(1):F161-9.

5. Naveen VMK, Veeraswami B, Srinivasa Rao G. High Response Bio-Analytical Validation approach of Nadolol and Bendroflumethiazide by LC-MS/MS on Rat plasma. International Journal of Research in Pharmaceutical Sciences. 2020;11(SPL4):2272-2279.

6. Naveen VMK, Veeraswami B, Srinivasa Rao G. Bio analytical validation for Nadolol and Bendroflumethiazide material. Mat. Tod. Proce. 2021;46(1):503-505.

7. Veeraswami B, Naveen VMK, Development and validation of RP-HPLC method for the estimation of Dolutegravir and Rilpivirine in bulk and pharmaceutical dosage form and its application to rat plasma. Asian J. Pharm. Clin. Res. 2019; 12(2):267-271.

8. Naveen VMK, Veeraswami B. Highly accurate and New approach for quantification of Gramicidin in medication by RP-HPLC. International Journal of Research in Pharmaceutical Sciences. 2020;11(SPL4):3053-3058.

9. Naveen VMK, Veeraswami B, Srinivasa Rao G. High Response Bio-Analytical Validation approach of Nadolol and Bendroflumethiazide by LC-MS/MS on Rat plasma. International Journal of Research in Pharmaceutical Sciences. 2020;11(SPL4):2272-2279.

10. Naveen VMK, Veeraswami B, Srinivasa Rao G. Bio analytical validation for Nadolol and Bendroflumethiazide material. Mat. Tod. Proce. 2021;46(1):503-505.

11. Veeraswami B, Naveen VMK, Development and validation of RP-HPLC method for the estimation of Dolutegravir and Rilpivirine in bulk and pharmaceutical dosage form and its application to rat plasma. Asian J. Pharm. Clin. Res. 2019; 12(2):267-271.

12. Naveen VMK, Veeraswami B. Highly accurate and New approach for quantification of Gramicidin in medication by RP-HPLC. International Journal of Research in Pharmaceutical Sciences. 2020;11(SPL4):3053-3058.

© 2021 Veeraswami and Naveen: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/77287